

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
March 29, 2021**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES ACT OF 1933**

**Constellation Pharmaceuticals, Inc.**

**File No. 333-225822 - CF#36248**

Constellation Pharmaceuticals, Inc. submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on June 22, 2018, as amended.

Based on representations by Constellation Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.10                      through April 27, 2031

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Robert Errett  
Acting Chief, Disclosure Management Office